Jeroen MD - Mendus AB Chief Officer
| IMMU Stock | SEK 8.15 0.03 0.37% |
Insider
Jeroen MD is Chief Officer of Mendus AB
| Age | 52 |
| Phone | 46 87 32 84 00 |
| Web | https://www.mendus.com |
Mendus AB Management Efficiency
The company has return on total asset (ROA) of (0.1114) % which means that it has lost $0.1114 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2053) %, meaning that it generated substantial loss on money invested by shareholders. Mendus AB's management efficiency ratios could be used to measure how well Mendus AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Oskar Bosson | BioArctic AB | 47 | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Marcuss | Cantargia AB | N/A | |
| Associate Gier | Xbrane Biopharma AB | N/A | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Samuel Wagner | Xbrane Biopharma AB | N/A | |
| Johanna Flting | BioArctic AB | 51 | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Gunilla Osswald | BioArctic AB | 62 | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Christer Mller | BioArctic AB | 64 | |
| Pr Lannfelt | BioArctic AB | 74 | |
| Adnan Deronic | Cantargia AB | N/A | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Anette Lindqvist | Xbrane Biopharma AB | 57 | |
| Gunilla Andersson | BioArctic AB | 62 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Maria Edebrink | Xbrane Biopharma AB | 54 | |
| Jan Mattsson | BioArctic AB | 63 | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.11 |
Mendus AB Leadership Team
Elected by the shareholders, the Mendus AB's board of directors comprises two types of representatives: Mendus AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mendus. The board's role is to monitor Mendus AB's management team and ensure that shareholders' interests are well served. Mendus AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mendus AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Bus Advisor | ||
| Leopold Bertea, Chief Officer | ||
| Lotta Ferm, Chief Officer | ||
| Erik Manting, Chief Officer | ||
| Jeroen MD, Chief Officer | ||
| PerOlof Gunnesson, Advisor Contracts | ||
| Alex MD, CoFounder Officer |
Mendus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mendus AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (69.15) % | |||
| Current Valuation | 607.17 M | |||
| Shares Outstanding | 199.4 M | |||
| Shares Owned By Insiders | 57.54 % | |||
| Shares Owned By Institutions | 11.78 % | |||
| Price To Earning | (4.53) X | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 354.29 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.